< Back to previous page

Project

Creation of a preclinical platform at the UA for testing novel therapeutic approaches against ocular surface diseases.

Ocular Surface diseases (OSD) such as dry eye syndrome (DES) show an estimated prevalence between 15 and 29%. The only FDA approved and on subscription dry-eye treatment is cyclosporine 0.05% (Restasis®), but this formulation is not available in the EU. Novel therapies for OSD are therefore needed. The expertise within ADDN fosters a unique opportunity to set up a preclinical platform on OSD leading to an increased collaboration with industrial partners.
Date:1 Jan 2014 →  31 Dec 2015
Keywords:DRUG DISCOVERY, OPHTHALMOLOGY, FORMULATION, PROTEASES
Disciplines:Chemical product design and formulation, Biomaterials engineering, Ophthalmology and optometry